These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
442 related articles for article (PubMed ID: 27390150)
1. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Genovese MC; Smolen JS; Weinblatt ME; Burmester GR; Meerwein S; Camp HS; Wang L; Othman AA; Khan N; Pangan AL; Jungerwirth S Arthritis Rheumatol; 2016 Dec; 68(12):2857-2866. PubMed ID: 27390150 [TBL] [Abstract][Full Text] [Related]
2. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. Kremer JM; Emery P; Camp HS; Friedman A; Wang L; Othman AA; Khan N; Pangan AL; Jungerwirth S; Keystone EC Arthritis Rheumatol; 2016 Dec; 68(12):2867-2877. PubMed ID: 27389975 [TBL] [Abstract][Full Text] [Related]
3. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829 [TBL] [Abstract][Full Text] [Related]
4. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202 [TBL] [Abstract][Full Text] [Related]
5. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230 [TBL] [Abstract][Full Text] [Related]
6. VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. Genovese MC; van Vollenhoven RF; Pacheco-Tena C; Zhang Y; Kinnman N Arthritis Rheumatol; 2016 Jan; 68(1):46-55. PubMed ID: 26473751 [TBL] [Abstract][Full Text] [Related]
7. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Kavanaugh A; Kremer J; Ponce L; Cseuz R; Reshetko OV; Stanislavchuk M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P Ann Rheum Dis; 2017 Jun; 76(6):1009-1019. PubMed ID: 27993828 [TBL] [Abstract][Full Text] [Related]
8. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260 [TBL] [Abstract][Full Text] [Related]
9. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials. Vanhoutte F; Mazur M; Voloshyn O; Stanislavchuk M; Van der Aa A; Namour F; Galien R; Meuleners L; van 't Klooster G Arthritis Rheumatol; 2017 Oct; 69(10):1949-1959. PubMed ID: 28622463 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669 [TBL] [Abstract][Full Text] [Related]
12. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. Mohamed MF; Camp HS; Jiang P; Padley RJ; Asatryan A; Othman AA Clin Pharmacokinet; 2016 Dec; 55(12):1547-1558. PubMed ID: 27272171 [TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Weinblatt ME; Mease P; Mysler E; Takeuchi T; Drescher E; Berman A; Xing J; Zilberstein M; Banerjee S; Emery P Arthritis Rheumatol; 2015 Oct; 67(10):2591-600. PubMed ID: 26138593 [TBL] [Abstract][Full Text] [Related]
15. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978 [TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Kremer JM; Bloom BJ; Breedveld FC; Coombs JH; Fletcher MP; Gruben D; Krishnaswami S; Burgos-Vargas R; Wilkinson B; Zerbini CA; Zwillich SH Arthritis Rheum; 2009 Jul; 60(7):1895-905. PubMed ID: 19565475 [TBL] [Abstract][Full Text] [Related]
17. Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate. Kivitz AJ; Gutierrez-Ureña SR; Poiley J; Genovese MC; Kristy R; Shay K; Wang X; Garg JP; Zubrzycka-Sienkiewicz A Arthritis Rheumatol; 2017 Apr; 69(4):709-719. PubMed ID: 27748083 [TBL] [Abstract][Full Text] [Related]
18. ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study. Genovese MC; Weinblatt ME; Aelion JA; Mansikka HT; Peloso PM; Chen K; Li Y; Othman AA; Khatri A; Khan NS; Padley RJ Arthritis Rheumatol; 2018 Nov; 70(11):1710-1720. PubMed ID: 29855172 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Zhou Y; Othman AA; Pangan AL; Kitamura S; Meerwein S; Tanaka Y Rheumatology (Oxford); 2020 Nov; 59(11):3303-3313. PubMed ID: 32277824 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Cohen SB; Cheng TT; Chindalore V; Damjanov N; Burgos-Vargas R; Delora P; Zimany K; Travers H; Caulfield JP Arthritis Rheum; 2009 Feb; 60(2):335-44. PubMed ID: 19180516 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]